Maravai LifeSciences Holdings, Inc.

Q2 2026 revenue was $51.4 million, up 9% year over year. Adjusted gross margin was 58.9%, expanding more than 1,600 basis points year over year. Adjusted EBITDA was $8.7 million, up $19.1 million year over year. GAAP net loss before noncontrolling interest was $21.6 million versus $69.8 million a year ago. Basic and diluted loss per share was $0.08 versus $0.27 last year, and adjusted EPS was a loss of $0.02 versus a loss of $0.08. For the full year, management kept revenue guidance at $205 million to $215 million, raised adjusted EBITDA guidance to $33 million to $35 million, and said gross margin improvement should be greater than 1,400 basis points. TriLink is expected to grow in the high teens, while Cygnus is expected to grow low to mid-single digits.

Bernd Brust framed the quarter as evidence that Maravai has “fundamentally changed” its earnings profile, citing stronger execution, a better mix, and operating leverage. He highlighted innovation launches such as GMP-grade enzymes and the upcoming GMP-grade ModTail, plus record customer adds and stronger e-commerce adoption. His tone was upbeat but measured, repeatedly emphasizing that large GMP and CDMO orders are inherently lumpy and that management is being prudent on revenue assumptions.

Rajesh Asorpota emphasized margin flow-through and balance sheet repair, noting GAAP net loss before noncontrolling interest improved to $21.6 million, adjusted EBITDA was $8.7 million, and cash ended at $70.1 million with debt at $147.1 million. He said the debt refinance extended maturities to 2032 and that the company expects further gross margin expansion, now projecting more than 1,400 basis points of improvement for 2026. He described the EBITDA guide raise as a confidence update rather than a change in conservative revenue assumptions, since large GMP and CDMO orders are program-driven and timing can vary significantly.

Analysts focused on why revenue guidance was unchanged despite better trends, and management said the decision was purely prudence because large project-driven orders can move between quarters. Questions also centered on the timing and revenue contribution of GMP ModTail and the new enzyme launch; management said GMP ModTail will be available later this year but they do not expect orders until 2027, while the enzyme launch is already producing its first shipped order. Additional questions covered MockV, e-commerce, and the new TriLink subsegment disclosure, with management saying MockV is still small but growing, e-commerce is performing better than expected, and the new framework is meant to give investors more visibility into TriLink growth drivers.